Skip header and navigation

2 records – page 1 of 1.

Biomarkers: project update from the GRAPPA 2012 annual meeting.

https://arctichealth.org/en/permalink/ahliterature108285
Source
J Rheumatol. 2013 Aug;40(8):1453-4
Publication Type
Conference/Meeting Material
Date
Aug-2013
Author
Oliver FitzGerald
Philip J Mease
Author Affiliation
Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College, Dublin, Ireland. oliver.fitzgerald@ucd.ie
Source
J Rheumatol. 2013 Aug;40(8):1453-4
Date
Aug-2013
Language
English
Publication Type
Conference/Meeting Material
Keywords
Arthritis, Psoriatic - diagnosis - metabolism - radiography
Biological Markers - metabolism
C-Reactive Protein
Disease Progression
Humans
Matrix Metalloproteinase 3
Predictive value of tests
Sweden
Abstract
For members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), an important goal has been the identification of soluble biomarkers in psoriatic arthritis that might predict the development of radiographic progression. Work over the past year has resulted in approval of a draft protocol, and an announcement is forthcoming of the outcome of an assessment process for centers that applied to manage the project. GRAPPA is now ready to commence formal negotiations with potential funding partners and intends to initiate this project in the near future.
PubMed ID
23908545 View in PubMed
Less detail

Composite Measures in Psoriatic Arthritis: a report from the GRAPPA 2009 annual meeting.

https://arctichealth.org/en/permalink/ahliterature101828
Source
J Rheumatol. 2011 Mar;38(3):540-5
Publication Type
Article
Date
Mar-2011
Author
Philip S Helliwell
Oliver Fitzgerald
C Vibeke Strand
Philip J Mease
Author Affiliation
University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK. p.helliwell@leeds.ac.uk
Source
J Rheumatol. 2011 Mar;38(3):540-5
Date
Mar-2011
Language
English
Publication Type
Article
Keywords
Arthritis, Psoriatic - drug therapy - pathology - physiopathology
Congresses as topic
Humans
Severity of Illness Index
Treatment Outcome
Abstract
A composite measure is one way of incorporating an assessment of all relevant clinical outcomes into one single measure. By definition it incorporates several dimensions of disease status often by combining these different domains into a single score. Such instruments are well established in rheumatoid arthritis (RA), and these RA-specific measures have successfully been adopted for use in clinical trials involving patients with psoriatic arthritis (PsA). However, the need for a more PsA-specific composite measure has led to a number of proposals, which, for the large part, incorporate only peripheral articular disease activity. New indices that combine the diverse clinical manifestations of PsA are now under development. These issues were discussed at the 2009 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) in Stockholm, Sweden, and are summarized here.
PubMed ID
21362782 View in PubMed
Less detail